二十二碳六烯酸治疗非酒精性脂肪性肝病患者疗效观察*

doi:10.3969/j.issn.1672-5069.2015.05.025

Abstract

Wang Yuzhe, Liu Zhiquan, Zhang Haicong, et al.. Docosahexaenoicacid in treatment of patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 542-543.

[1] 文晗，王海俊，董彬，等. 内肥素与儿童青少年肥胖非酒精性脂肪肝的关联研究. 中华流行病学杂志，2012，24（3）:269-272.
[2] 张晓敏，万燕萍，徐仁应，等. 不同时期上海市高中生肥胖及非酒精性脂肪性肝病比较分析. 临床儿科杂志，2010，28（9）:823-826.
[3] Smith AD. Liver cirrhosis mortality rates in Britain. Lancet， 2006，367（9526）:1898-1899.
[4] 刘鹏亮，王炳元.青少年脂肪肝:狂饮与肥胖. 实用肝脏病杂志，2012，15（3）:189-190.
[5] 郑娉娉，王炳元. 非酒精性脂肪性肝病与酒精性肝病的异同. 中华肝脏病杂志，2011，19（9）:715-717.
[6] 周健，刘黎，黄丽雯，等. 牛磺熊去氧胆酸治疗非酒精性脂肪肝疗效观察. 实用肝脏病杂志，2014，17（1）:80-81.
[7] 王东霞. 复方甘草酸苷联合中药汤剂治疗非酒精性脂肪肝临床观察. 中华肝脏病杂志，2012，15（2）:135-136.
[8] 冯凯瑜. 复方牛胎肝提取物治疗非酒精性脂肪肝临床观察. 实用肝脏病杂志，2014，17（3）:311-312.
[9] Nobili V，Bedogni G，Alisi A，et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease:double-blind randomised controlled clinical trial. Arch Dis Childhood，2011，96（4）:350-353.
[10] 曹万新，孟橘，田玉霞. DHA 的生理功能及应用研究进展. 中国油脂，2011，36（3）:1-4.
[11] 李秀丽. 非酒精性脂肪肝病的药物治疗研究. 时珍国医国药， 2010，17（12）:3228-3229.
[12] 夏菁，孙涛. 非酒精性脂肪肝发病机制及治疗研究进展. 海军总医院学报，2010，23（2）:100-103.
[13] Zhang X，Yeung DCY，Karpisek M，et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes，2008，57（5）:1246-1253.
[14] 周婷婷，秦波，郑天鹏，等. 非酒精性脂肪肝患者血浆 FGF21 水平及与肥胖、胰岛素抵抗关系研究. 第三军医大学学报， 2010，22（3）:265-268.
[15] Liu W Y，Huang S，Shi K Q，et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease:a novel predictor and therapeutic target. Expert Opin Therapeut Targets，2014，18（11）:1305-1313.

Docosahexaenoicacid in treatment of patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[2]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[3]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[4]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[5]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[6]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[7]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[8]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[9]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[10]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[11]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[12]	Xie Zhanfeng, Jia Jizhen, Zhao Shufang. Combination of notoginseng total saponin and silybin in treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 623-624.
[13]	Yang Yan, Wang Xuan. Diagnosis and treatment of patients with diabetic hepatopathy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 653-656.
[14]	Zhao Wentao, Cao Gaofeng, Jiao Xiaohong, et al. Efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease and prediabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 409-412.
[15]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.